Olanzapine: Interpreting the label change

International Journal of Clinical Practice

Volumn 61, Issue 12, 2007, Pages 1960-1962

  Citrome, L ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; OLANZAPINE; PLACEBO;

BODY FAT; BODY WEIGHT; DIABETES MELLITUS; DRUG EFFICACY; DRUG LABELING; DRUG METABOLISM; DRUG SAFETY; EDITORIAL; GENETIC PREDISPOSITION; GLUCOSE BLOOD LEVEL; HUMAN; PRESCRIPTION; PRIORITY JOURNAL;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DRUG LABELING; HUMANS; WEIGHT GAIN;

EID: 35948939626     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01631.x     Document Type: Editorial

References (14)

1. Eli Lilly and Company. Press Release: Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels, 5 October, 2007. http://newsroom.lilly.com/ ReleaseDetail.cfm?ReleaseID=267502 (accessed October 2007).
2. Eli Lilly and Company. Dear Health Care Professional: Safety Data on Zyprexa (Olanzapine) and Symbyax (Olanzapine and Fluoxetine HCl Capsules) - Hyperglycemia, Weight Gain, and Hyperlipidemia, 5 October, 2007. http://www.insidezyprexa.com/pdf/Dear_HCP_Letter.pdf (accessed October 2007).
3. Eli Lilly and Company. Zyprexa Olanzapine Tablets, Zyprexa Zydis Olanzapine Orally Disintegrating Tablets, Zyprexa IntraMuscular Olanzapine for Injection, 1 October, 2007. http://pi.lilly.com/us/zyprexa-pi.pdf (accessed October 2007).
4. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003 60 : 553 64.
5. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 353 : 1209 23.
6. Mintz J, Kopelowicz A. CUtLASS confirms CATIE. Arch Gen Psychiatry 2007 64 : 978.
7. Tiihonen J, Walhbeck K, Lonnqvist J et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006 333 : 224 7.
8. Kinon BJ, Kaiser CJ, Ahmed S et al. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 2005 25 : 255 8.
9. Citrome L, Yoemans D. Do guidelines for severe mental illness promote physical health and well-being J Psychopharmacol 2005 19 (6 Suppl. 102 9.
10. Citrome L, Holt RIG, Zachry WM et al. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. Ann Pharmacother 2007 41 : 1593 603.
11. Citrome L, Stroup TS. Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians? Int J Clin Pract 2006 60 : 933 40.
12. Citrome L. Show me the evidence: using number needed to treat. South Med J 2007 100 : 881 4.
13. Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry 2006 59 : 990 6 (Epub 20 December 2005).
14. Czobor P, Volavka J, Sheitman B et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol 2002 22 : 244 51.